Alyftrek is a medicine for cystic fibrosis in people 6 and older with certain gene changes. It is taken as tablets once a day. It helps the faulty CFTR protein get to the cell surface and work better, so mucus in the lungs and other organs is less thick and sticky.
Every report comes from a Lived member, sent anonymously.
Have you tried Alyftrek (Vanzacaftor / Tezacaftor / Deutivacaftor) for Cystic Fibrosis?
Alyftrek is a once-daily tablet that combines three medicines, vanzacaftor, tezacaftor and deutivacaftor, to treat cystic fibrosis (CF) in people aged 6 and older. CF is an inherited disease in which a faulty protein called CFTR (cystic fibrosis transmembrane conductance regulator) makes mucus in the lungs, pancreas, intestines and other organs thick and sticky. Alyftrek belongs to a group of medicines called CFTR modulators, which work on that faulty protein itself rather than only easing its effects. It is approved for people who have a clinical diagnosis of CF and at least one CFTR gene variant that responds to the drug or still produces some CFTR protein. The most common qualifying variant is F508del, and the label lists hundreds of others, including many rare ones. If a person's genetic results are not known, an FDA-cleared CF genetic test is used to confirm eligibility. Having an eligible variant is not enough by itself; the medicine is meant only for people who actually have CF. Alyftrek was approved in the US in 2024. Its main trials compared it with Trikafta (elexacaftor, tezacaftor and ivacaftor), a widely used three-drug CF modulator taken twice a day.
In healthy cells lining the airways, gut and sweat glands, CFTR sits on the cell surface and works as a channel for chloride, one of the components of salt. In CF, the protein is either misshapen and too little of it reaches the cell surface, or it reaches the surface but its channel does not open properly. Either way, salt handling goes wrong and mucus thickens. Alyftrek addresses both problems. Vanzacaftor and tezacaftor are correctors: they attach to different parts of the CFTR protein and help more of it get processed and delivered to the cell surface. Deutivacaftor is a potentiator: it helps the channels that do reach the surface open more often. Deutivacaftor is a chemically modified version of ivacaftor, an earlier CF potentiator. Together they increase both the amount and the activity of CFTR, which shows up as a lower sweat chloride, a measure of salt in sweat that reflects how well CFTR is working.
Alyftrek is taken by mouth once a day, at about the same time each day, with food that contains fat. Fat helps the body absorb it, so a meal or snack prepared with butter or oil, or one that includes eggs, peanut butter, cheese, nuts, whole milk or meat, is suitable. The tablets are swallowed whole, not split, chewed or crushed. The tablet strength and number depend on age and weight. People 12 and older, and children 6 to 11 who weigh at least 40 kg (about 88 pounds), take two tablets of the higher strength. Children 6 to 11 who weigh less take three tablets of a lower strength. Some interacting medicines require a much smaller or less frequent dose, so any change in other prescriptions should be checked with the prescriber. If a dose is missed and no more than 6 hours have passed since the usual time, take it with fat-containing food as soon as possible. If more than 6 hours have passed, skip it and take the next dose at the usual time the next day. Do not take two doses to make up for one.
In the main trials, the most common side effects were cough, cold-like symptoms such as a stuffy or runny nose and sore throat, sinus congestion, headache, flu, tiredness and rash. Many of these overlap with everyday CF symptoms, and most occurred at similar rates in people taking Trikafta. Rash was somewhat more frequent with Alyftrek (about 11 in 100 people, compared with about 8 in 100 on Trikafta) and was more common in women. Hormonal birth control may play a part, so a rash in someone using it is worth raising with the care team. Most rashes were mild to moderate. Some changes show up only on blood tests: raised liver enzymes in about 9 in 100 people in the trials, and raised creatine phosphokinase, an enzyme released from muscle. A small share of people also had a rise in blood pressure. Anxiety, depression, trouble sleeping and, in some cases, suicidal thoughts or behavior have been reported since approval with Alyftrek and related CF medicines, in people with and without a history of these problems, often within the first three months. Contact the prescriber right away about new or worsening mood changes, thoughts of self-harm or trouble sleeping. Severe allergic reactions, including anaphylaxis, have been reported rarely with related CF medicines. Swelling of the face, lips, tongue or throat, or trouble breathing or swallowing, needs emergency care.
Alyftrek carries the FDA's most serious type of warning, a boxed warning, for liver injury. Raised liver enzymes occur with Alyftrek, and serious liver injury, including liver failure that led to transplant or death, has been reported with Trikafta, which contains the same or similar ingredients. That injury appeared anywhere from the first month to 15 months after starting. This is why regular liver blood tests are required. Stop the medicine and call the prescriber immediately for yellowing of the skin or eyes, dark urine, pain or discomfort in the upper right belly, nausea or vomiting, loss of appetite, or confusion. Alyftrek should not be used by people with severe liver disease and is generally not recommended for those with moderate liver disease. An unusual headache, blurred or double vision, or vision loss can be a sign of raised pressure around the brain (intracranial hypertension), which has been reported with related medicines; report these to the prescriber right away. Cataracts (clouding of the eye's lens) have been reported in children taking ivacaftor-containing medicines, so children and teenagers have eye exams before and during treatment. Alyftrek is broken down by a liver enzyme called CYP3A, so medicines that change that enzyme change how much Alyftrek is in the body. Products that speed it up, such as St. John's wort (an herbal supplement), can make Alyftrek less effective and are not recommended. Medicines that slow it, such as itraconazole (an antifungal), raise Alyftrek levels, so the dose has to be cut, in some cases to one dose a week. Grapefruit and grapefruit juice should be avoided. Alyftrek may also raise levels of some other drugs; people taking warfarin, a blood thinner, need more frequent INR checks, the blood test that shows how long blood takes to clot. Tell the CF team and pharmacist about every prescription, over-the-counter medicine, vitamin and supplement. There is no information yet on Alyftrek in pregnancy or breastfeeding in people; animal studies did not show harm to developing offspring. Anyone pregnant, planning pregnancy or breastfeeding should discuss it with the CF team. People who stopped Trikafta or a related medicine in the past because of side effects were not studied with Alyftrek and need closer monitoring if they try it.
Alyftrek is meant to be taken long term. It controls CF but does not cure it, so it is continued even when a person feels well, and stopping should be discussed with the CF team first. In the two main year-long trials, people aged 12 and older who were already taking and tolerating Trikafta either switched to Alyftrek or stayed on Trikafta. Lung function was measured as ppFEV1 (percent predicted forced expiratory volume in one second), how much air a person can blow out in one second compared with what is expected for someone of the same age, sex and height. It stayed essentially the same in both groups, which is what the trials were designed to show. Sweat chloride fell further on Alyftrek, by roughly 3 to 8 mmol/L more than on Trikafta, suggesting CFTR worked somewhat better. Lung flare-ups and breathing-related quality of life were similar. For someone already doing well on Trikafta, the practical gains are once-daily dosing and a possibly lower sweat chloride rather than a proven further improvement in breathing. There are no comparable trial results for people starting a CF modulator for the first time, and benefit in children 6 to 11 is inferred from older patients and from drug levels. Monitoring is part of treatment. Liver blood tests are done before starting, every month for the first 6 months, every 3 months for the next 12 months, and at least once a year after that, more often for people with past liver problems. Children and teenagers have eye exams before starting and during treatment.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Alyftrek (Vanzacaftor / Tezacaftor / Deutivacaftor), what you've noticed, or ask the community a question.